INAB Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

IN8bio Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerINAB

Market Cap17.6M

Cash RunwayRunway > 12 months

Next Catalyst2027-01

Public Research Snapshot

IN8bio Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for INB-400 (Phase 2).

Pipeline

Asset	Indication	Modality	Stage	Public Note
INB-400	n/a	n/a	Phase 2	Public pipeline row
INB-200	n/a	Cell Therapy	Phase 1	Public pipeline row
INB-100	n/a	n/a	n/a	Public pipeline row
IINB-400	n/a	n/a	Phase 2	Public pipeline row
INB-300	n/a	n/a	Preclinical	Public pipeline row
EAGD T-cell infusion (Phase I)	n/a	Cell Therapy	Phase 1	Public pipeline row
Autologous genetically modified gamma-delta T cells	Glioblastoma	n/a	Phase 1 \| Phase 2	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2027-01	EAGD T-cell infusion (Phase I)	Low

Cash Runway Preview

Estimated cash runway: Runway > 12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT05664243	Phase 1 \| Phase 2	ACTIVE_NOT_RECRUITING	4	2025-12
NCT03533816	Phase 1	RECRUITING	38	2027-01

Scientific Context

asset_name | Autologous genetically modified gamma-delta T cells
clinical_stage | Phase 1 | Phase 2
clinical_stage | Phase 1 | Phase 2
indication | Glioblastoma
indication | Glioblastoma

Want the full INAB research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.